256381-13-2 Usage
Also known as
4-bromomethcathinone
Classification
Substituted cathinone class
Type
Psychoactive drug and designer drug
3. Effects on the central nervous system
Similar to
Amphetamines and MDMA
4. Usage
Commonly used as
Recreational drug
Methods of ingestion
Oral, inhalation, or injection
5. Stimulating and psychedelic effects
Increased energy
Mental alertness
Euphoria
6. Potential negative effects
Increased heart rate
Elevated blood pressure
Neurotoxicity
7. Legal status
Potential for abuse
High
Adverse health effects
Present
Illegal in many countries
Yes
Listed as controlled substance
Yes
Check Digit Verification of cas no
The CAS Registry Mumber 256381-13-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,5,6,3,8 and 1 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 256381-13:
(8*2)+(7*5)+(6*6)+(5*3)+(4*8)+(3*1)+(2*1)+(1*3)=142
142 % 10 = 2
So 256381-13-2 is a valid CAS Registry Number.
256381-13-2Relevant articles and documents
NRF2 ACTIVATOR
-
Page/Page column 113; 116, (2018/08/20)
Provided are tetrahydroisoquinoline derivatives as Nrf2 activators.
Synthesis, biological evaluation and molecular modelling of sulfonohydrazides as selective PI3K p110α inhibitors
Kendall, Jackie D.,Rewcastle, Gordon W.,Frederick, Raphael,Mawson, Claire,Denny, William A.,Marshall, Elaine S.,Baguley, Bruce C.,Chaussade, Claire,Jackson, Shaun P.,Shepherd, Peter R.
, p. 7677 - 7687 (2008/03/14)
A series of 2-methyl-5-nitrobenzenesulfonohydrazides were prepared and evaluated as inhibitors of PI3K. An isoquinoline derivative shows good selectivity for the p110α isoform over p110β and p110δ, and also demonstrates good in vitro activity in a cell pr
Biarylpropylsulfonamides as novel, potent potentiators of 2-amino-3-(5-methyl-3-hydroxyisoxazol-4-yl)-propanoic acid (AMPA) receptors [1]
Ornstein,Zimmerman,Arnold,Bleisch,Cantrell,Simon,Zarrinmayeh,Baker,Gates,Tizzano,Bleakman,Mandelzys,Jarvie,Ho,Deverill,Kamboj
, p. 4354 - 4358 (2007/10/03)
-
